Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2

Effective treatment or vaccine is not yet available for combating SARS coronavirus 2 (SARS-CoV-2) that caused the COVID-19 pandemic. Recent studies showed that two drugs, Camostat and Nafamostat, might be repurposed to treat COVID-19 by inhibiting human TMPRSS2 required for proteolytic activation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Haixia, Du, Wenhao, Song, Menghua, Liu, Qing, Herrmann, Andreas, Huang, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Research Network of Computational and Structural Biotechnology 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809394/
https://www.ncbi.nlm.nih.gov/pubmed/33505639
http://dx.doi.org/10.1016/j.csbj.2020.12.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7809394/
https://www.ncbi.nlm.nih.gov/pubmed/33505639
http://dx.doi.org/10.1016/j.csbj.2020.12.035

Ejemplares similares